Figure 2.
Cumulative incidence of prostate cancer-specific mortality in patients receiving radiation with neoadjuvant-concurrent androgen deprivation therapy, stratified by a detectable end-of-radiation PSA level. Blue curve represents men with an undetectable end-of-radiation PSA level. Red curve represents men with a detectable end-of-radiation PSA level.
